You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞銀首予歐康維視生物-B(01477.HK)「買入」評級 目標價34.2元
阿思達克 04-01 09:38
瑞銀發表的研究報告,首予歐康維視生物(01477.HK)「買入」評級,認為眼科藥市場快速發展加上在創新眼科藥物上競爭溫和,相信公司主要強勢在於其多元、創新的產品,可覆蓋各種眼疾,加上其商用化能力或可降本增效。該行估計公司今年將在內地推創新藥YUTIQ,認為現時其估值低於同業,市場忽略了公司OT-401加快獲批的影響,同時亦未反映其產品線帶來的潛在增長。

該行指出2019年內地眼科藥物市場規模為28億美元,相當於美國市場的五分之一,料到2030年將增長至169億美元,意味年複合增長達17.8%,相信增長主要是受惠於創新藥推出,滿足到醫療需求,不過現時內地僅數家眼科藥生產商是專注於創新藥,而歐康維視生物覆蓋的眼疾則是同業中最廣。

該行指出公司商業化團隊有69人,覆蓋267家醫院,去年4至12月收入達1,310萬元人民幣,按季增長達215.5%,核心產品YUTIQ估計加快至今年獲批,予公司目標價34.2元,評級「買入」。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account